ArticleClinical and translational radiation oncology2022

Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.

Jean-Michel Hannoun-Levi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.